Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 9/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | HTR7 | P34969 | 1/20 | 0.68 |
| ▸ | GFER | P55789 | 1/20 | 0.67 |
| ▸ | THRA | P10827 | 1/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | DRD2 | P14416 | 1/20 | 0.62 |
| ▸ | HTR2A | P28223 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11828902 | 0.91 | HTR1A (0.68) | HTR1AHTR7DRD2HTR2A | |
| SCHEMBL16026463 | 0.90 | KMT2A (0.83) | HTR1AKMT2AALDH1A1MAPTGFER | |
| Hydrochloric Acid SCHEMBL9274815 | 0.90 | HTR1A (0.67) | HTR1AKMT2AALDH1A1MAPTHTR7 | |
| SCHEMBL11756285 | 0.89 | HTR1A (0.70) | HTR1AHTR7DRD2HTR2A | |
| Hydrochloric Acid SCHEMBL7934846 | 0.88 | KMT2A (0.83) | HTR1AKMT2AALDH1A1MAPTGFER | |
| SCHEMBL6358223 | 0.86 | HTR1A (1.00) | HTR1AKMT2AALDH1A1MAPTTHRA | |
| SCHEMBL2114983 | 0.85 | HTR1A (0.73) | HTR1AALDH1A1MAPTHTR7DRD2 | |
| SCHEMBL12123756 | 0.84 | HTR1A (0.82) | HTR1ATHRATHRB | |
| SCHEMBL11628917 | 0.84 | HTR1A (0.61) | HTR1AMAPTHTR7DRD2HTR2A | |
| SCHEMBL351380 | 0.83 | POLB (0.74) | HTR1AKMT2AALDH1A1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287009-A1 | AMINE-FUNCTIONAL MONOMERS AND METHODS OF MAKING SAME | INFINEUM INTERNATIONAL LIMITED (GB) | 2024-08-29 | — | — | US | disclosed |
| EP-4410772-A2 | AMINE-FUNCTIONAL MONOMERS AND METHODS OF MAKING SAME | Infineum International Limited (GB) | 2024-08-07 | — | — | EP | disclosed |
| CN-118440229-A | Amine functional monomers and methods of making the same | 英菲诺姆国际有限公司 | 2024-08-06 | — | — | CN | disclosed |
| US-20160060235-A1 | Therapeutic Agent for Type 2 Diabetes | NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) | 2016-03-03 | — | — | US | disclosed |
| US-20160060235-A1 | Therapeutic Agent for Type 2 Diabetes | NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) | 2016-03-03 | — | — | US | disclosed |
| US-20120016124-A1 | SEROTONIN REUPTAKE INHIBITORS | BAYLOR UNIVERSITY (US) | 2012-01-19 | — | — | US | disclosed |
| US-7893261-B2 | bi-functional organic molecules which combine serotonin transporter reuptake inhibition with serotonin (5-HT, such as 5-HT2A) receptor antagonism in one molecular entity | BAYLOR UNIVERSITY (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893261-B2 | bi-functional organic molecules which combine serotonin transporter reuptake inhibition with serotonin (5-HT, such as 5-HT2A) receptor antagonism in one molecular entity | BAYLOR UNIVERSITY (US) | 2011-02-22 | — | — | US | disclosed |
| US-20080132514-A1 | Serotonin Reuptake Inhibitors | BAYLOR UNIVERSITY | 2008-06-05 | — | — | US | disclosed |
| US-20080132514-A1 | Serotonin Reuptake Inhibitors | BAYLOR UNIVERSITY | 2008-06-05 | — | — | US | disclosed |
| EP-1732610-A2 | TARGETED SEROTONIN REUPTAKE INHIBITORS | BAYLOR UNIVERSITY (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005094896-A2 | TARGETED SEROTONIN REUPTAKE INHIBITORS | BAYLOR UNIVERSITY (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2005-08-11 | — | — | US | disclosed |
| US-4065565-A | Acylhydrazones and anti-psychotic compositions thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1977-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016124-A1 | SEROTONIN REUPTAKE INHIBITORS | HTR2A, HTR2C, HTR1A | HTR1A 3/4885KMT2A 839/4885ALDH1A1 969/4885 |
| US-20240287009-A1 | AMINE-FUNCTIONAL MONOMERS AND METHODS OF MAKING SAME | AMD1, HNMT, MAT1A | HTR1A 857/4885KMT2A 134/4885ALDH1A1 317/4885 |
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | CYP19A1, SHBG, CYP17A1 | HTR1A 871/4885KMT2A 1762/4885ALDH1A1 199/4885 |
| US-20080132514-A1 | Serotonin Reuptake Inhibitors | HTR2A, HTR2C, HTR1A | HTR1A 3/4885KMT2A 839/4885ALDH1A1 969/4885 |
| US-20160060235-A1 | Therapeutic Agent for Type 2 Diabetes | RNASE1, CDKL2, CDKL1 | HTR1A 4839/4885KMT2A 903/4885ALDH1A1 3775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.